Dr. Sohn to Oversee Development of Next Gen COVID-19 Vaccine to Treat Kidney Failure Patients, Late-Stage Rabies Therapeutic and Age-related Macular Degeneration

Boca Raton, FL, October 12, 2021 — Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that Dr. Catherine Sohn has joined the Company as a Special Advisor to the Board of Directors and the CEO.

Dr. Sohn is President of Sohn Health Strategies and Adjunct Professor at the University of California, San Francisco, her alma mater, where she received her Doctor of Pharmacy degree and the Distinguished Alumnus Award (2000).  Dr. Sohn is currently Chairman of BioEclipse Therapeutics, a privately held, clinical-stage oncology company and is an independent Director on the Board of Directors of Jazz Pharmaceuticals plc (NASDAQ), Rubius Therapeutics (NASDAQ), Axcella Health (NASDAQ), Landec Corp (NASDAQ) and privately held Maze Therapeutics.

Dr. Sohn has deep biopharmaceutical industry knowledge with over thirty years of U.S. and global experience, and a reputation as a strategic thinker with the ability to drive a strong interface between research & development and marketing. Her expertise includes the development and introduction of new medicines for patients and diseases with significant unmet needs. Her skill sets include strategic product development, business development and the introduction of new vaccines, pharmaceutical products and consumer healthcare brands.

Dr. Sohn started the U.S. Vaccine Business for SmithKline Beecham and led the launch of its first vaccine in the U.S. and helped shape their global vaccine portfolio pipeline as a member of the International Vaccine Steering Committee.  Subsequently, she led the US commercialization of the company’s largest CNS product.  Dr. Sohn later became senior vice president, Worldwide Business Development and a member of the global executive committee at GlaxoSmithKline Consumer Healthcare where she led U.S. and global transactions, including the $1.3 billion acquisition and integration of Block Drug and the $566 million acquisition of CNS, Inc. Before that, she was Vice President Worldwide Strategic Product Development for the cardiovascular, pulmonary and metabolic therapeutic areas at SmithKline Beecham Pharmaceuticals responsible for portfolio prioritizations and overseeing the global launch of Coreg for congestive heart failure which became a $1 billion indication.

Paul Michaels, Chairman and President of Curative Biotech stated “We are obviously extremely pleased to have Dr. Sohn on board to oversee our infectious disease programs and our macular degeneration program.  Dr. Sohn will also act as the Chairman for the joint steering committees for all three clinical programs.  Her impressive background and experience at the highest levels of our industry speaks for itself, and her long involvement in developing novel vaccines will prove invaluable as we develop our next generation Covid-19 vaccine to treat kidney failure patients.”

Dr. Catherine Sohn added, “Curative Biotechnology has an innovative business model focused on moving therapeutics through development at an accelerated pace.  Their use of reformulated metformin to treat degenerative eye disease is a prime example.  Their novel immunomodulatory drug IMT504 may provide a desperately needed treatment option for Rabies patients who have lapsed beyond the treatment window for conventional Rabies shots.  Their novel next generation COVID-19 vaccine for kidney failure patients is also a sorely needed treatment as COVID-19 and its multiple variations continue to roll through our population.  I am excited to begin working with the Company on all of these promising programs.”


Future Curative Biotechnology Press Releases and Industry Updates

Interested investors and shareholders will receive press releases and industry updates by sending an e-mail to ir@curativebiotech.com.


About Curative Biotechnology, Inc. http://curativebiotech.com

Curative Biotech is a development-stage biomedical company focusing on novel treatments for rare or currently unmet medical needs. Curative Biotech is focused on therapies with potentially accelerated development paths resulting from either the disease, the nature of the therapeutic itself, or the stage of clinical development. At the heart of the Company is a product development engine that rests on our unique S.O.A.R. filter (Science, Opportunity, Acceleration, Rare Disease.) At Curative Biotech, we envision a world where all patients have a therapeutic option.


Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. CUBT is not yet generating revenues. Although forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subjected to known, unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements, including but not limited our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with OTC Markets from time to time which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Tags: Immunologic, Orphan Drug, Glioblastoma, Metformin, macular degeneration (AMD), immunocompromised, NIH, NEI, NCI, IMT504, National Institutes of Health, Rabies, FDA, cancer, Kidney, dialysis, Biotechnology, Monoclonal Antibody, Transplant, Vaccine, COVID-19

Contact Information:
Steve Chizzik Investor Relations Curative Biotech (CUBT) 201-454-5845 ir@curativebiotech.com

Financial Content, ReleaseLive, PR-Wirein, Google News, Reportedtimes, Menafn, IPS, iCN Internal Distribution, English